Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

The authors discuss the financial repercussions of using ocrelizumab, a more expensive anti-CD20 monoclonal antibody, compared to rituximab for treating multiple sclerosis (MS). Between 2018 and 2021, they estimate that Medicare and Medicaid could have saved $2.5 billion if ocrelizumab were priced similarly to rituximab.